Low-concentration atropine eye drops delay myopia onset
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current interventions are inadequate for preventing or delaying the onset of myopia, particularly in children, with existing treatments like atropine eye drops showing side effects and limited effectiveness in inhibiting myopia progression once it has begun.
Innovation Solution
A composition comprising atropine at concentrations of 0.001% to 0.5%, preferably 0.05% to 0.01%, administered for extended periods to children aged 4 to 12 years to inhibit or delay the onset of myopia, with specific criteria for subjects including spherical equivalent refraction and astigmatism levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 1% atropine eye drops are used to reduce myopia progression, then myopia progression is reduced by 77%, but side effects include cycloplegia and pupil dilatation resulting in blurred near vision and photophobia
Solution Approach 1:
The patent applies parameter changes by reducing the atropine concentration from 1% to lower concentrations (0.5%, 0.1%, 0.05%, 0.01%). This parameter modification maintains the therapeutic effect of reducing myopia progression while minimizing the harmful side effects of cycloplegia and photophobia. The ATOM 2 study demonstrated that lower concentrations achieve comparable efficacy with significantly reduced adverse effects.
Solution Approach 2:
The patent employs partial action by using sub-maximal concentrations of atropine (particularly 0.01% and 0.05%) that provide sufficient therapeutic effect for myopia control without causing excessive pharmacological action. This partial action approach achieves the desired outcome (myopia progression reduction) with minimal side effects, avoiding the need for full 1% concentration.
2Reliability
If atropine eye drops are used to treat myopia progression, then efficacy is improved, but there is no effective intervention for inhibiting or delaying the onset of myopia
Solution Approach 1:
The patent applies preliminary action by administering atropine eye drops before the onset of myopia or at the very early stage (pre-myopia phase). The study recruited children with spherical equivalent from +0.50D to -0.50D, treating them before full myopia develops. This preliminary intervention delays myopia onset and reduces progression, addressing the time loss issue by acting early in the disease course.
3Object-affected harmful factors
If low-concentration atropine (0.01%) is used to reduce side effects, then photophobia and blurred near vision are minimized, but the effectiveness in reducing myopia progression is reduced
Solution Approach 1:
The patent systematically evaluates different concentration parameters (0.5%, 0.1%, 0.05%, 0.01%) to find the optimal balance between efficacy and side effects. The ATOM 2 study results showed that 0.01% atropine achieves 50% of the efficacy of 1% atropine with minimal side effects, while 0.05% provides a balanced compromise. This parameter optimization resolves the contradiction by identifying the concentration that maximizes benefit-risk ratio.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution effectively delays the onset of myopia for several years, reducing myopia incidence and progression, as demonstrated by significant reductions in spherical equivalent refraction and axial length changes, with minimal side effects.
Implementation Method 1
Atropine is a nonselective muscarinic receptor antagonist with many postulated mechanisms for its anti-myopia actions, including its biochemical effects on the retina and sclera for eyeball remodeling
Data Source
AI summary
The subject invention pertains to compositions comprising atropine at a concentration of greater than 0.025% to about 0.05% and methods of administering said compositions to a subject to inhibit or delay the onset of myopia in pre-myopic patients.